Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three traditional Chinese medicine (TCM) ingredients—Astragalus (commonly Astragalus membranaceus), Panax notoginseng, and Borneol. Astragalus and Panax notoginseng are widely used in TCM for their anti-inflammatory, immunomodulatory, neuroprotective, and cardiovascular effects. The main active components are astragaloside IV from Astragalus and saponins from Panax notoginseng. Borneol is a terpene that acts as a penetration enhancer to facilitate the delivery of other compounds across the blood-brain barrier. Preclinical studies show that this combination can reduce cerebral ischemia-reperfusion injury by promoting neurogenesis, regulating microglial polarization toward an anti-inflammatory phenotype (M2), inhibiting pro-inflammatory pathways such as TLR4/MyD88/NFκB signaling, reducing infarct volume in stroke models, and improving neurological function. The addition of borneol enhances the brain penetration of active components from Astragalus and Panax notoginseng[1][2]. This combination has also been studied for potential benefits in chronic kidney disease when combined with other herbs[3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on astragalus + panax notoginseng + borneol.